IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have earned an average rating of “Moderate Buy” from the seventeen research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and fifteen have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $48.6875.

A number of brokerages have commented on IDYA. Citigroup boosted their target price on IDEAYA Biosciences from $64.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. UBS Group assumed coverage on IDEAYA Biosciences in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target for the company. Wall Street Zen cut IDEAYA Biosciences from a “buy” rating to a “sell” rating in a research note on Saturday, February 21st. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Finally, Guggenheim reaffirmed a “buy” rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th.

Insider Activity at IDEAYA Biosciences

In other IDEAYA Biosciences news, Director Jeffrey Stein purchased 50,000 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were bought at an average price of $32.96 per share, for a total transaction of $1,648,000.00. Following the purchase, the director directly owned 54,281 shares in the company, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On IDEAYA Biosciences

Several institutional investors and hedge funds have recently modified their holdings of IDYA. Farther Finance Advisors LLC increased its position in IDEAYA Biosciences by 171.1% during the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after buying an additional 580 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of IDEAYA Biosciences in the third quarter worth about $38,000. ANTIPODES PARTNERS Ltd lifted its position in shares of IDEAYA Biosciences by 49.4% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after buying an additional 380 shares during the last quarter. Abich Financial Wealth Management LLC bought a new stake in shares of IDEAYA Biosciences during the 3rd quarter worth about $58,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of IDEAYA Biosciences during the 2nd quarter worth about $61,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Down 3.5%

Shares of NASDAQ:IDYA opened at $30.53 on Wednesday. The firm has a fifty day moving average of $33.30 and a two-hundred day moving average of $31.92. IDEAYA Biosciences has a 12-month low of $13.45 and a 12-month high of $39.28. The firm has a market capitalization of $2.68 billion, a P/E ratio of -23.31 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.09. The company had revenue of $21.75 million during the quarter, compared to analyst estimates of $5.95 million. During the same period last year, the company posted ($1.49) earnings per share. The company’s revenue was up 55.7% compared to the same quarter last year. Equities research analysts expect that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.